BioCity Nottingham

The BioWell Accelerator, a First Bight-Led initiative, Receives Prestigious Federal Grant

Retrieved on: 
Mittwoch, Dezember 13, 2023
Maker, Longevity, Organization, Economic development, Entrepreneurship, Commerce, Ecosystem, UP, Partnership, CDC, Urban Partnership Bank, EDA, BioCity Nottingham, Greater Houston Partnership

HOUSTON, Dec. 13, 2023 /PRNewswire/ -- The U.S. Economic Development Administration, a division of the U.S. Department of Commerce, has awarded $53 million for its highly competitive "Build to Scale" Grant program to enhances and promotes venture activity and entrepreneurship for regional economies. Only 60 organizations were funded out of the many applications received. The Houston-based First Bight Ventures, and the founder of BioWell, a nonprofit accelerator aimed at early-stage synthetic biology startups, was awarded $741,925.

Key Points: 
  • The Houston-based First Bight Ventures, and the founder of BioWell , a nonprofit accelerator aimed at early-stage synthetic biology startups, was awarded $741,925.
  • "Startups at BioWell will gain access to a robust ecosystem, expertise, mentorship, and financial resources essential for successfully commercializing their bio-industrial innovations," said BioWell Executive Director Paul Palmer.
  • BioWell is committed to offering startups key business and operational resources and face-to-face engagement with large corporations.
  • Because BioWell is still in its infancy as an accelerator, it is actively trying to secure resources with the goal of opening a dedicated workspace.

Riding the tide, realize the future: The BD paths for Chinese Biotech

Retrieved on: 
Mittwoch, November 15, 2023
Chronic kidney disease, DDR, Observation, Research, Policy, Return, Spacecraft, Biology, ROI, Kidney disease, Disease, ADC, Climate, Risk, Learning, Technology policy, Patient, Multinational corporation, Science, Partner, PD-1, Return on investment, Partnership, BIC, CMO, FIC, Metabolic disorder, Growth, BioCity Nottingham, Business, Face, Health, Philosophy, Pharmaceutical industry, Typesetting, Fine chemical, Sales, Risk management, Guardian

Form both angles, he shared his views on Chinese biotech transformation and the key points and prospects of BD collaboration between Chinese biotech and MNCs.

Key Points: 
  • Form both angles, he shared his views on Chinese biotech transformation and the key points and prospects of BD collaboration between Chinese biotech and MNCs.
  • The clear recognition of the success of this approach is evident by the recent partnerships between multiple multinational pharma and relatively small Chinese biotech companies.
  • Q: What are MNCs prioritizing for potential collaborations, and what are the key points to be taken for Chinese biotech?
  • We have now begun to reach out to MNCs to socialize our clinical stage programs to explore potential partnership paths.

BioCity Signs Collaboration Agreement with AstraZeneca on BC3402, a monoclonal antibody targeting anti-TIM-3, in Combination with IMFINZI (durvalumab) for the Treatment of Advanced Hepatocellular Carcinoma in China

Retrieved on: 
Donnerstag, September 28, 2023
University of the Chinese Academy of Sciences, Phosphatidylserine, Hook effect, Survival, Cancer, Chinese Academy of Medical Sciences COVID-19 vaccine, Zhongshan Hospital, AstraZeneca, Liver cancer, CEACAM1, Patient, National Medical Products Administration, Mab, Epitope, PD-1, IND, NMPA, HCC, BioCity Nottingham, Safety, Pharmaceutical industry, Durvalumab

BioCity will lead the trial, which has received IND approval by the National Medical Products Administration (NMPA).

Key Points: 
  • BioCity will lead the trial, which has received IND approval by the National Medical Products Administration (NMPA).
  • Moreover, BC3402 has shown synergistic anti-cancer activity with mAbs targeting PD-1 and CTLA-4, which are important clinical targets for liver cancer.
  • The collaboration between BioCity and AstraZeneca will evaluate the potential for the combination of BC3402 with durvalumab to improve the clinical outcome of subjects with HCC.
  • Both companies may be expected to explore further collaboration opportunities to boost innovation in China in HCC and possibly other types of cancer.

BioCity announces FDA clearance of Investigational New Drug application for its first-in-class CD3/EGFR bispecific antibody

Retrieved on: 
Montag, August 7, 2023
Bispecific monoclonal antibody, KRAS, CD3, CRS, BRAF, NSCLC, Investigational New Drug, Cytokine release syndrome, Patient, EGFR, HNSCC, BioCity Nottingham, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Safety, Pharmaceutical industry, Vaccine

WUXI, China, Aug. 7, 2023 /PRNewswire/ -- BioCity Biopharma today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for a Phase 1 study of BC3448 (CD3/EGFR Bispecific antibody, BsAb).

Key Points: 
  • WUXI, China, Aug. 7, 2023 /PRNewswire/ -- BioCity Biopharma today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for a Phase 1 study of BC3448 (CD3/EGFR Bispecific antibody, BsAb).
  • As a result, BioCity Biopharma will initiate a dose escalation/expansion study with BC3448, enrolling patients with advanced solid tumors in the United States.
  • BC3448 is a CD3-based BsAb that recruits T cells to tumors cells with high EGFR expression resulting in T cell-driven tumor cell killing.
  • Opening of the US IND by BioCity will accelerate the clinical development of this innovative cancer therapy globally.

Scottish Biotech ILC Therapeutics Sets Sights on Series A and IPO After Recent Investment Round

Retrieved on: 
Mittwoch, April 26, 2023
Health, COVID-19, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, GSK, IPO, Hepatitis, Partnership, University, Urinary tract infection, HIV, SARS-CoV-2, Dermatitis, Infection, ICL, Skin, CTA, Atopic dermatitis, Multimedia, Respiratory syncytial virus, Psoriasis, RSV, University of Strathclyde, Dog, Series, Preclinical development, Growth, Immunology, Scottish Enterprise, Therapy, VC, Eos, BioCity Nottingham, ILC, Vaccine, Management, Pharmaceutical industry

Scottish biotech ICL Therapeutics has set its sights on a Series A round and an IPO following its most recent investment round, and is on track to commercialise a suite of anti-viral medicines for the treatment of respiratory infections including SARS-CoV-2.

Key Points: 
  • Scottish biotech ICL Therapeutics has set its sights on a Series A round and an IPO following its most recent investment round, and is on track to commercialise a suite of anti-viral medicines for the treatment of respiratory infections including SARS-CoV-2.
  • An additional £2 million round led by existing investors was subsequently completed in Q4 of 2022.
  • One of Scotland’s most pioneering biotechs, ILC is also expected to embark on a Series A investment round over the next twelve months, with a view to a possible post-investment round IPO.
  • ILC has appointed Dr Owain Millington as Vice President and Head of Preclinical Development, who has a long career in life sciences leadership teams.

Sampled’s Genomics Laboratory in Glasgow Launches Inaugural Project with Guardant Health

Retrieved on: 
Mittwoch, Februar 1, 2023
Health, Genetics, Science, Research, Oncology, SHIELD, Standard BioTools, Laboratory, Helmy Eltoukhy, Trial of the century, Sample, Abraxis BioScience, PerkinElmer, Thermo Fisher Scientific, Patient, Heart, Lung cancer, BioCity Nottingham, Genomics, Ageing, Medical imaging, Illumina

Sampled1 today announced that the new genomics Sampled SMART Lab in Glasgow, UK, has initiated a project with Guardant Health, Inc., a leading precision oncology company, to manage blood samples for a large-scale lung cancer screening study.

Key Points: 
  • Sampled1 today announced that the new genomics Sampled SMART Lab in Glasgow, UK, has initiated a project with Guardant Health, Inc., a leading precision oncology company, to manage blood samples for a large-scale lung cancer screening study.
  • The SHIELD Lung registrational study is designed to evaluate the performance of a Guardant blood-based screening test to detect lung cancer in high-risk individuals aged 50-80.
  • “This project is a major milestone towards making Sampled’s world-class capabilities available around the world.
  • The state-of-the-art, 3,000 square foot biosample research and analysis lab was created to bring Sampled Smart Labs service offerings to European clients.

BellaSeno Starts Two Clinical Trials of its Resorbable Breast and Chest Implants

Retrieved on: 
Donnerstag, August 4, 2022
Medtech, University, BioCity Nottingham, Polycaprolactone, ISO, Senior lecturer, Quality of life, HBI, Pectus excavatum, BMBF, Patient, Company, Pain, Safety, Tissue, Hospital, Regional development, PCL, University of Queensland, SAB, Government, Education, Committee on European Affairs and Oversight of the European Funds, Solution, Health, Certification, Princess Alexandra Hospital, CMO, Princess Alexandra Hospital, Brisbane, Environment, CBCI, Medical device, Medical imaging, Royal Brisbane and Women's Hospital, Research

BellaSeno already published first-in-human data in 2021, demonstrating that its implant was able to camouflage a pectus excavatum defect not reconstructable by conventional techniques.

Key Points: 
  • BellaSeno already published first-in-human data in 2021, demonstrating that its implant was able to camouflage a pectus excavatum defect not reconstructable by conventional techniques.
  • The second trial aims to enroll 20 patients who either need breast implant revision or surgery to correct congenital breast defects.
  • In both trials, patients will receive porous polycaprolactone implants produced in Bellasenos AI-driven additive manufacturing facilities by a no-touch approach.
  • The Company is developing novel resorbable soft tissue and bone reconstruction implants made by additive manufacturing (3D-printing) under ISO 13485 certification.

Sampled Expand Global Footprint with New Lab in UK

Retrieved on: 
Donnerstag, Juni 30, 2022
Health, Health Technology, Other Health, Other Science, Research, Science, Biotechnology, Acquisition, BioCity Nottingham, Heart, Research, Genomics, Transport, SMART, Health, PCR, Fine chemical, Illumina, Sample

Infinity BiologiX LLC d/b/a Sampled SMART Labs, open new lab in Glasgow, UK.

Key Points: 
  • Infinity BiologiX LLC d/b/a Sampled SMART Labs, open new lab in Glasgow, UK.
  • The facility, based in Glasgow, UK, is a state-of-the-art 3000sqft biosample research and analysis lab focused on the delivery of Sampled Smart Labs service offerings to European clients.
  • Since the acquisition of Roylance Pharma on the same site and subsequent rebranding to Sampled, this expansion is the first major step in proudly rolling out our Sampled SMART Labs in the UK.
  • This opening sets the tone for how we will look to further expand our business and the Sampled SMART Labs concept globally, said Robin Grimwood, Sampled CEO.

BellaSeno Announces Publication of First-in-Human Data of its Lead Program Senella

Retrieved on: 
Dienstag, Dezember 7, 2021
Environment, Risk, Company, Pectus excavatum, Queensland University of Technology, BMBF, CMO, Plastic surgery, BioCity Nottingham, University, Medtech, SAB, Patient, CEO, Committee on European Affairs and Oversight of the European Funds, Deformity, Princess Alexandra Hospital, Government, Education, Certification, Princess Alexandra Hospital, Brisbane, ISO, Senior lecturer, Polycaprolactone, Regional development, Doctor of Philosophy, European Journal, University of Queensland, Breast, PCL, Medical imaging

Leipzig, Germany, December 07, 2021 BellaSeno GmbH , an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced the publication of first-in-human data of its lead program Senella in the European Journal of Plastic Surgery .

Key Points: 
  • Leipzig, Germany, December 07, 2021 BellaSeno GmbH , an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced the publication of first-in-human data of its lead program Senella in the European Journal of Plastic Surgery .
  • The highly porous polycaprolactone implant was well tolerated by the patient and resulted in an excellent aesthetic outcome.
  • The case study describes the first-in-human trial of soft tissue engineering to camouflage a pectus excavatum defect not reconstructable by conventional techniques.
  • Senella therefore has the potential to alleviate the complications found in current breast reconstruction and augmentation approaches.

Mannin GmbH Implements CDD Vault Informatics Platform to Facilitate Data Management and Collaboration

Retrieved on: 
Mittwoch, November 24, 2021
Gesellschaft mit beschränkter Haftung, API, IOP, Eye, Data management, Collaborative Drug Discovery, Biology, Subversive activities registration, Degenerative disease, Cystic kidney disease, Inflammation, SAN, Therapy, Representational state transfer, Database, Electronic lab notebook, ELN, Isle of Man, Research, CDD, Activity, BioCity Nottingham, Organization, SAR, Medicinal chemistry, Drug discovery, Chemistry, Pharmaceutical industry

CDD Vault, a hosted chemistry and biology research data management platform developed by Collaborative Drug Discovery, Inc. (CDD), will be used to manage all the company's research data and collaborative projects across geographies.

Key Points: 
  • CDD Vault, a hosted chemistry and biology research data management platform developed by Collaborative Drug Discovery, Inc. (CDD), will be used to manage all the company's research data and collaborative projects across geographies.
  • CDD Vault is a hosted platform designed to manage drug discovery data including small molecules and biologics, as well as all the related experimental and contextual information.
  • It also includes a documented RESTful API that enables organizations to integrate CDD Vault with other software tools.
  • CDD Vault is a hosted database solution for secure management and sharing of biological and chemical data.